Clinical trial / 2010
Lactobacillus gasseri A5 supplementation improved pulmonary function, symptom scores, and inflammatory cytokines in children with asthma and allergic rhinitis.
School children aged 6-12 years with asthma and allergic rhinitis were randomized to receive Lactobacillus gasseri A5 (n = 49) or placebo (n = 56) daily for 2 months. Compared with controls, probiotic-treated patients showed significant increases in pulmonary function and peak expiratory flow rates, alongside decreased clinical symptom scores for asthma and allergic rhinitis. In addition, probiotic treatment resulted in significant reductions in TNF-α, IFN-γ, IL-12, and IL-13 production by peripheral blood mononuclear cells.
- Study type
- Randomized, double-blind, placebo-controlled study
- Who was studied
- 105 school children (age 6-12 years) with asthma and allergic rhinitis (49 probiotic, 56 placebo)
- What was measured
- Pulmonary function, PEFR, asthma and allergic rhinitis symptoms, and PBMC cytokine production
THE PAPER
Randomized placebo-controlled trial of lactobacillus on asthmatic children with allergic rhinitis.
Chen YS, Jan RL, Lin YL, Chen HH, Wang JY. Pediatr Pulmonol, 2010.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.